Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05498103 · ClinicalTrials.gov registry record · Phase 4

Use of Methazolamide to Lower Intraocular Pressure

A Phase 4 study of Glaucoma Open-Angle, sponsored by University of Colorado, Denver.

Active
Registry status
Phase 4
Development phase
30
Enrollment target
1
Study location

NCT05498103 is a Phase 4 study of Glaucoma Open-Angle that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 30 participants, below the 164-participant average among 22 other Glaucoma Open-Angle trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05498103, a Phase 4 study of Glaucoma Open-Angle, is active but no longer recruiting, sponsored by University of Colorado, Denver.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the effect of methazolamide, 25 mg or 50 mg tablets once a day for a week than twice a day for a week, on lowering intraocular pressure and the safety of methazolamide.

Conditions Studied

Interventions

  • DRUG Methazolamide 25 MG
  • DRUG Methazolamide 50 MG

Study Locations (1)

Colorado

  • Sue Anschutz-Rodgers Eye Center - Aurora

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2023-02-17
Est. Completion 2024-12
Phase Phase 4

Sponsor

University of Colorado, Denver

1,283 total trials

What the Registry Record Tells You About NCT05498103

The ClinicalTrials.gov registry entry for NCT05498103 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 164-participant average among 22 other Glaucoma Open-Angle trials with a reported enrollment target (82% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Glaucoma Open-Angle appearing as the primary indexed condition, and to 2 interventions - of which Methazolamide 25 MG is the first listed.

NCT05498103 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT05498103 about?

NCT05498103 is a clinical study titled "Use of Methazolamide to Lower Intraocular Pressure". The purpose of this study is to evaluate the effect of methazolamide, 25 mg or 50 mg tablets once a day for a week than twice a day for a week, on lowering intraocular pressure and the safety of methazolamide.

What is the current status of trial NCT05498103?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2023-02-17. Estimated completion is 2024-12.

What conditions does trial NCT05498103 study?

This clinical trial studies the following conditions: Glaucoma Open-Angle.

What interventions are being tested in trial NCT05498103?

The interventions under investigation include: Methazolamide 25 MG (DRUG), Methazolamide 50 MG (DRUG).

Who is sponsoring clinical trial NCT05498103?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05498103 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Glaucoma Open-Angle

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.